Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-03-31

Study Completion Date

2003-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial was conducted in the United States of America (USA). The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

NCT01847989

Congenital Bleeding Disorder Congenital FXIII Deficiency Healthy

COMPLETED PHASE1

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

NCT00713648

Congenital Bleeding Disorder Congenital FXIII Deficiency

COMPLETED PHASE3

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

NCT00978380

Congenital Bleeding Disorder Congenital FXIII Deficiency

COMPLETED PHASE3

Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

NCT01848002

Congenital Bleeding Disorder Congenital FXIII Deficiency Healthy

COMPLETED PHASE1

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

NCT01230021

Congenital Bleeding Disorder Congenital FXIII Deficiency

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Bleeding Disorder Congenital FXIII Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rFXIII

Group Type EXPERIMENTAL

catridecacog

Intervention Type DRUG

Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

catridecacog

Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documental congenital FXIII deficiency
* Normal platelet count and clotting parameters
* Adequate renal and hepatic function
* If female and of child-bearing potential, negative serum pregnancy test within 7 days of enrollment
* If a sexually active male or a sexually active female of child-bearing potential, agreement to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits
* Negative drug and alcohol screens

Exclusion Criteria

* Received blood products or FXIII concentrates within 4 weeks of study enrollment
* Known antibodies to FXIII
* Hereditary or acquired coagulation disorder other than FXIII deficiency
* Previous history of autoimmune disorders involving autoantibodies e.g., systemic lupus erythematosus
* Previous history of thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis or administration of any antithrombotic or antiplatelet drugs within 7 days of study enrollment
* Received treatment with any experimental agent within 30 days of study enrollment
* Any surgical procedure in the 30 days prior to enrollment
* Donated blood within 30 days prior to enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No